News
ATNM
5.16
+0.98%
0.05
Actinium Pharmaceuticals Granted U.S. Patent #11,364,235 Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5393&f=G&l=50&d=PTXT&p=108&S1=20220621&OS=20220621&RS=20220621
Benzinga · 06/21 10:26
Has Alkermes (ALKS) Outpaced Other Medical Stocks This Year?
Here is how Alkermes (ALKS) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Zacks · 05/19 13:40
BRIEF-Actinium Presents Data From Phase 3 SIERRA Trial
reuters.com · 04/25 11:37
Actinium Pharmaceuticals, Inc. Announces 82% of Control Arm Patients Did Not Receive a Bone Marrow Transplant by Conventional Means but 100% of Patients who Received Iomab-B, Including Crossover Patients, in the Phase 3 SIERRA Trial Successfully Engrafted at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs today highlighted data from full patient enrollment in the pivotal Phase 3 SIERRA trial of I...
PR Newswire · 04/25 11:30
BRIEF-Actinium Pharmaceuticals Inc To Highlight IOMAB-B Pivotal Phase 3 Sierra Trial Data At The Transplantation & Cellular Therapy Tandem Meetings Of Astct And Cibmtr
reuters.com · 04/19 11:33
Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs today highlighted its activity at the upcoming Transplantation & Cellular Therapy (TCT) Tand...
PR Newswire · 04/19 11:30
Actinium (ATNM) Up on Commercialization Deal With Immedica
Actinium (ATNM) out-licenses exclusive rights to Iomab-B, an antibody radiation conjugate for facilitating bone-marrow transplant, to Immedica in Europe, the Middle East and North African countries.
Zacks · 04/13 19:36
Actinium maintained at outperform at William Blair following Immedica Pharma deal
William Blair is maintaining Actinium Pharmaceuticals at outperform after the company's license and supply agreement with Immedica Pharma AB for Iomab-B. That agreement, announced Tuesday, provides Actinium (NYSE:ATNM) with a
Seekingalpha · 04/13 19:34
--Alliance Global Adjusts Price Target on Actinium Pharmaceuticals to $25 From $20, Maintains Buy Rating
MT Newswires · 04/13 05:40
Biotech Stocks News: What’s Going on With LIXT, PTE, QLGN and ATNM Stocks Today?
Investor Place · 04/12 18:15
AIM, PTE and PHIO among mid-day movers
Gainers: Lixte Biotechnology Holdings (LIXT) +205%. PolarityTE (PTE) +96%. Biodesix (BDSX) +29%. MiNK Therapeutics (INKT) +27%. Enservco (ENSV) +25%. Actinium Pharmaceuticals (ATNM) +21%. Compass Therapeutics (CMPX) +21%. Sunshine Biopharma (SBFM)
Seekingalpha · 04/12 16:48
Sector Update: Health Care Stocks Ending Near Intra-Day Lows
MT Newswires · 04/12 15:57
Lixte, BioCardia top healthcare gainers; Hoth, Altamira lead losers' pack
Gainers: Lixte Biotechnology (LIXT) +263%. BioCardia (BCDA) +29%. Biodesix (BDSX) +27%. Aeglea BioTherapeutics (AGLE) +16%. Actinium Pharmaceuticals (ATNM) +14%. Losers: Hoth Therapeutics (HOTH) -30%. Altamira Therapeutics (CYTO) -29%. Myovant Sciences (MY...
Seekingalpha · 04/12 14:02
Sector Update: Health Care Stocks Drifting Lower Tuesday Afternoon
MT Newswires · 04/12 13:50
Actinium gains on agreement with Immedica Pharma for conditioning agent
Clinical-stage biotech Actinium Pharmaceuticals (NYSE:ATNM) and Swedish pharma group, Immedica Pharma AB announced an agreement for Iomab-B, a drug combination being developed for targeted conditioning in bone marrow transplant and
Seekingalpha · 04/12 11:32
BRIEF-Actinium Pharmaceuticals, Immedica Announce Commercialization Agreement For Iomab-B
reuters.com · 04/12 11:31
Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs, and Immedica Pharma AB ("Immedica") today announced entering a license and supply agreement...
PR Newswire · 04/12 11:00
Top Premarket Gainers
MT Newswires · 04/12 08:14
Actinium Pharmaceuticals Signs License, Supply Agreement for Iomab-B With Immedica Pharma
MT Newswires · 04/12 07:50
BRIEF-Actinium Pharmaceuticals Presents Preclinical Data Related To Her3 Targeted Radiotherapy
reuters.com · 04/11 11:54
More
Webull provides a variety of real-time ATNM stock news. You can receive the latest news about Actinium Pharmac through multiple platforms. This information may help you make smarter investment decisions.
About ATNM
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on Antibody Radiation-Conjugates (ARCs), which combine the targeting ability of antibodies with the cell-killing ability of radiation. Its clinical programs are focused on two primary areas: targeted conditioning prior to bone marrow transplant, adoptive cell or gene therapies and therapeutics, in combination with other therapeutic modalities. Its clinical pipeline is focused on ARCs targeting the antigens CD45 and CD33, both of which are expressed in multiple hematologic cancers. Its lead CD45-targeted conditioning product candidate, Iomab-B, via the monoclonal antibody BC8, targets CD45, an antigen expressed on leukemia and lymphoma cancer cells, B cells and stem cells. Its CD33 program is evaluating the clinical utility of Actimab-A, an ARC consisting of the anti-CD33 mAb lintuzumab linked to the potent alpha-emitting radioisotope Actinium-225 (Ac-225).